Výsledky vyhledávání - "Atsushi Utsuno"

A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

Autor: Eiji Ueyama, Satoshi Yoshida, H. Ishikawa, Hideyuki Takahashi, Kenichi Kazuta, Atsunori Kashiwagi, Atsushi Utsuno

Publikováno v: Diabetes, Obesity and Metabolism. 17:152-160

Aims To assess the effects of renal impairment (RI) on the efficacy and safety of ipragliflozin in patients with type 2 diabetes mellitus (T2DM). Methods A cohort of Japanese patients with T2DM and mild to moderate RI and poor glycaemic control, desp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71b23c4a25f44baca1210d6127bca9e4
https://doi.org/10.1111/dom.12403

Zobrazit plný text záznamu

Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study

Autor: Atsunori Kashiwagi, Eiji Ueyama, Kenichi Kazuta, Noriko Akiyama, Satoshi Yoshida, Takanori Shiga, Atsushi Utsuno

Publikováno v: Diabetology International. 6:125-138

Sulfonylureas are often used alone or in combination with other drugs for treating type 2 diabetes. Ipragliflozin is a sodium/glucose cotransporter 2 inhibitor that enhances urinary glucose excretion and improves glycemic control. We examined the eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc735c6439d5a2d0da007dd8f5690b42
https://doi.org/10.1007/s13340-014-0184-9

Zobrazit plný text záznamu

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

Autor: Noriko Akiyama, Atsunori Kashiwagi, Atsushi Utsuno, Kenichi Kazuta, Eiji Ueyama, Satoshi Yoshida, Takanori Shiga

Publikováno v: Diabetology International. 6:104-116

Ipragliflozin is a novel oral sodium–glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of type 2 diabetes. We examined its efficacy and safety as an add-on to pioglitazone in Japanese patients with inadequately controlle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53c710606cc7622ea72d721512d95bb0
https://doi.org/10.1007/s13340-014-0182-y

Zobrazit plný text záznamu

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study

Autor: K. Goto, Atsunori Kashiwagi, Eiji Ueyama, Kenichi Kazuta, Atsushi Utsuno, Satoshi Yoshida

Publikováno v: Diabetes, Obesity & Metabolism

This multicenter, double-blind, placebo-controlled study examined the efficacy and safety of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with metformin in Japanese patients with type 2 diabetes mellitus (T2DM). Patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90b52d205c323d3865b6b98c5da7e16
http://europepmc.org/articles/PMC4342773

Zobrazit plný text záznamu

Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects

Autor: Atsushi Utsuno, Shigeru Kageyama, Shigenori Kawasaki, Takeshi Kadokura, Itsuro Nagase, Satoshi Yoshida, Masako Saito, Kenichi Kazuta

Publikováno v: Diabetology International. 2:172-182

This phase 1, randomized, placebo-controlled, dose-escalation study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ipragliflozin (ASP1941) in healthy Japanese subjects. Subjects received a single oral dose (1–300 mg)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::05cd125d328802f710543d56bb730e48
https://doi.org/10.1007/s13340-011-0037-8

Zobrazit plný text záznamu

Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study

Autor: Shigeru Kageyama, Satoshi Yoshida, Itsuro Nagase, Atsushi Utsuno, Ronald A. Smulders, Noriko Akiyama, Atsunori Kashiwagi, Kenichi Kazuta, Takeshi Kadokura

Publikováno v: Diabetes research and clinical practice. 106(1)

Aims Ipragliflozin is a novel and highly selective sodium–glucose transporter 2 (SGLT2) inhibitor that reduces plasma glucose levels by enhancing urinary glucose excretion in patients with type 2 diabetes mellitus (T2DM). We examined the pharmacoki

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b402f59d9fa58bba73dffb46d65c5106
https://pubmed.ncbi.nlm.nih.gov/25149596

Zobrazit plný text záznamu

Synthesis of the α and β anomer of an N-triglycosyl dipeptide

Autor: Naoki Okamoto, Atsushi Utsuno, Seiichi Shibata, Yukio Ogihara, Tadahiro Takeda

Publikováno v: Carbohydrate Research. 207:71-79

O-alpha-D-Glucopyranosyl-(1----6)-O-beta-D-glucopyranosyl-(1----6)-1-N- [L-aspart-1-oyl-(L-proline)-4-oyl]-alpha- and -beta-D-glucopyranosylamine have been prepared, as models for a derivative possibly present in the glomerular basement membrane of r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5bbd9d425b6200ffa75a9afc0deb5325
https://doi.org/10.1016/0008-6215(90)80006-o

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání